endpts.com·Apr 24, 2026
Avalyn Pharma is planning a $182 million IPO to support its development of inhaled versions of existing pulmonary fibrosis treatments, while Novartis' malaria drug has received prequalification from the WHO.
Avalyn Pharma's planned $182 million IPO to develop inhaled versions of approved pulmonary fibrosis medicines indicates a significant investment opportunity in respiratory health innovations. This move could be an actionable signal for stakeholders in biotech IPOs and respiratory medicine, as it highlights potential growth areas in inhaled drug delivery systems. Stay updated on Avalyn's progress and consider the implications for similar healthtech and biotech ventures.